The First Affiliated Hospital with Nanjing Medical University: Lymphoma, T-Cell, Peripheral trials

The registry lists 12 Lymphoma, T-Cell, Peripheral studies with The First Affiliated Hospital with Nanjing Medical University as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 4Phase 3 2No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Efficacy of CAPCT in Patients With PTCLNot yet recruitingNCT07746245Phase 2
• A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.Not yet recruitingNCT06953739Phase 3
• Chi-GVM Regimen for the Treatment of R/R PTCLRecruitingNCT06211881Not applicable
• A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCLRecruitingNCT05931263Phase 3
• CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell LymphomaRecruitingNCT05896813Not applicable
• The Whole-course Management of Pegaspargase in ENKTLNot yet recruitingNCT05426824Not applicable
• A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell LymphomaNot yet recruitingNCT05343377Not applicable
• Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell LymphomaStatus unknownNCT05774028Phase 2
• Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)Status unknownNCT05772728Not applicable
• LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell LymphomaTerminatedNCT04219319Phase 1
• Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma SubjectsStatus unknownNCT03629873Phase 2
• Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell LymphomaStatus unknownNCT02879526Phase 2